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Abstract
Background: Boron neutron capture therapy (BNCT) is a cellular-level particle radiation therapy that combines the
selective delivery of boron compounds to tumour tissue with neutron irradiation. L-p-Boronophenylalanine (L-BPA)
is a boron compound now widely used in clinical situations. Determination of the boron distribution is required for
successful BNCT prior to neutron irradiation. Thus, positron emission tomography with [18F]-L-FBPA, an 18F-labelled
radiopharmaceutical analogue of L-BPA, was developed. However, several differences between L-BPA and [18F]-L-
FBPA have been highlighted, including the different injection doses and administration protocols. The purpose of
this study was to clarify the equivalence between L-BPA and [19F]-L-FBPA as alternatives to [18F]-L-FBPA.
Methods: SCC-VII was subcutaneously inoculated into the legs of C3H/He mice. The same dose of L-BPA or [19F]-L-
FBPA was subcutaneously injected. The time courses of the boron concentrations in blood, tumour tissue, and
normal tissue were compared between the groups. Next, we administered the therapeutic dose of L-BPA or the
same dose of [19F]-L-FBPA by continuous infusion and compared the effects of the administration protocol on
boron accumulation in tissues.
Results: There were no differences between L-BPA and [19F]-L-FBPA in the transition of boron concentrations in
blood, tumour tissue, and normal tissue using the same administration protocol. However, the normal tissue to
blood ratio of the boron concentrations in the continuous-infusion group was lower than that in the subcutaneous
injection group.
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Conclusions: No difference was noted in the time course of the boron concentrations in tumour tissue and normal
tissues between L-BPA and [19F]-L-FBPA. However, the administration protocol had effects on the normal tissue to
blood ratio of the boron concentration. In estimating the BNCT dose in normal tissue by positron emission tomography
(PET), we should consider the possible overestimation of the normal tissue to blood ratio of the boron concentrations
derived from the values measured by PET on dose calculation.
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Background
Boron neutron capture therapy (BNCT) is based on the
nuclear reaction of the 10B nucleus, which absorbs low-
energy neutrons to produce two high-linear-energy
transfer particles (4He, 163 keV/μm and 7Li, 210 keV/
μm) from the 10B(n, α)7Li reaction. The track ranges of
these particles (5–9 μm) are limited to the diameter of a
single cell. Theoretically, therefore, if 10B atoms are
selectively accumulated in each tumour cell, and then
the volume including the tumour is exposed to a suffi-
ciently high fluence of thermal neutrons, targeting single
tumour cells with less normal tissue damage than
conventional therapy is possible [1]. Two boron com-
pounds, disodium mercaptoundecahydrododecaborate
(Na2B12H11SH; BSH) [2] and L-p-boronophenylalanine
(L-BPA) [3], have been clinically utilized for the treat-
ment of patients with various types of X-ray-refractory
cancers such as malignant melanoma [4], malignant
brain tumours [5–9], recurrent head and neck cancer
[10, 11], and malignant mesothelioma [12]. In contrast
to other types of radiotherapy, the cytocidal effect of
BNCT on tumour tissue depends on the selective accu-
mulation of boron compounds in the tumour. Thus,
imaging methods that can illuminate the distribution of
boron compounds noninvasively are important to forecast
the efficacy of BNCT.
o-[18F]-Fluoro-L-p-boronophenylalanine ([18F]-L-FBPA)
is an 18F-labelled radiopharmaceutical analogue of L-BPA
used as a positron emission tomography (PET) probe to
estimate the L-BPA distribution in BNCT using L-BPA
prior to treatment [13]. This “theranostic approach”,
which combines diagnostic modalities such as PET
imaging and a therapeutic procedure such as neutron ir-
radiation with boron compounds, is useful to confirm the
irradiation dose from the boron neutron capture reaction
and calculate the estimated tumour dose beforehand to
assure safety and efficacy. However, the method used to
evaluate the boron concentrations predicted by [18F]-L-
FBPA PET for L-BPA accumulation in both tumour tissue
and normal tissue has not been fully established because
of several uncertain differences between [18F]-L-FBPA and
L-BPA. First, the chemical structure and resulting physico-
chemical properties of [18F]-L-FBPA are not completely
the same as L-BPA (Fig. 1). Actually, the degree of solubil-
ity in water and affinity to L-BPA antibodies were different
between L-BPA for BNCT and [18F]-L-FBPA in a PET
study. The lipophilic feature of fluorine can affect the dis-
tribution in tissues in the biological viewpoint. Lipid solu-
bility of [18F]-L-FBPA is higher than that of L-BPA due to
the fluorine atom of [18F]-L-FBPA. Second, the
administered dose, solubilized form of compounds with
water, and measurement methods for the boron concen-
trations are different between L-BPA and [18F]-L-FBPA. A
high dose of L-BPA (250–900 mg/kg body weight) is
administered as the L-BPA-fructose complex to increase
the solubility in clinical situations [14], while a tracer dose
of [18F]-L-FBPA is used in [18F]-L-FBPA PET without
the formulation of the sugar complex. Continuous
therapeutic dose of infusion has the possibility to make
pharmacokinetic equilibrium saturate and alter the dis-
tribution of boron compounds in tissues compared to
single shot tracer dose of injection. The amount of ac-
cumulated [18F]-L-FBPA is mainly measured by PET
imaging because no other modality can detect tracer
Fig. 1 Chemical structure of L-BPA and its fluorine derivative for positron emission tomography. a L-BPA = L-p-boronophenylalanine, b L-FBPA =
o-fluoro-L-p-boronophenylalanine
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doses of the compound, while L-BPA concentrations
are measured by other methods such as prompt gamma
ray spectroscopy and inductively coupled plasma
atomic emission spectroscopy (ICP-AES). Third, L-BPA
is administered by continuous drip infusion over a
period of more than 3 h; in contrast, [18F]-L-FBPA is
administered as a single injection.
Some of these issues regarding the differences between
L-BPA and [18F]-L-FBPA have already been examined.
Regarding tumour tissue, Imahori showed that the boron
level in the tumour tissue estimated with [18F]-L-FBPA
PET method was closed to that of surgical specimens
directly measured after a single injection of L-BPA with
the prompt gamma method [15]. Regarding normal tis-
sue, Hanaoka and colleagues demonstrated that each
PET parameter of normal tissue after a tracer-dose sin-
gle injection of [18F]-L-FBPA showed good correlation
with the boron concentrations of normal tissue mea-
sured by ICP-AES after a single injection of L-BPA [16].
However, there are no previous reports that compare the
difference of boron accumulation in tissues between
[18F]-L-FBPA and L-BPA under the same injection dose,
the same administration protocol, and the same boron
measurement protocol. To show the validity of [18F]-L-
FBPA PET as an accurate prediction tool to estimate the
efficacy of BNCT with L-BPA before treatment, the
remaining clinical questions should be addressed. First,
what is the effect of the different injected doses of L-
BPA and [18F]-L-FBPA? Do the different solubilized
boron compounds (sugar-complex or not) affect the
boron concentrations in tumour and normal tissues? Is
there any other difference in the boron concentration in
hollow viscus, in which the accumulation of the PET
tracer is usually underestimated by PET imaging, and
what is the difference in the normal tissue to blood ratio
(N/B ratio), tumour to blood ratio (T/B ratio), or
tumour to normal tissue ratio (T/N ratio) of boron con-
centrations between the continuous-infusion protocol
used clinically and the single-injection protocol with
PET analysis?
To answer these questions, we synthesized the cold
stable isotope of [18F]-L-FBPA, [19F]-L-FBPA, using a
procedure for the large-scale synthesis of L-FBPA that
we previously developed because the chemical properties
of [19F]-L-FBPA and [18F]-L-FBPA are identical and 18F
is not necessary if the amount of L-FBPA in tissues is
measured by ICP-AES. In this study, we examined the
differences in the boron concentrations of the tumour
tissue and normal tissues between L-BPA and [19F]-L-
FBPA instead of [18F]-L-FBPA using the same dose, the
same boron measuring methods (ICP-AES), and the
same administration protocol as that for a subcutaneous
tumour mouse model. Next, we evaluated the difference
in the administration protocols between the single-
injection mouse model and the continuous-infusion
mouse model to clarify the remaining questions con-




Optically pure [19F]-L-FBPA was synthesised by a hybrid
process using L-aminoacylase from commercially avail-
able 2-fluoro-4-dihydroxyborylbenzaldehyde (Additional
file 1: Figure S1). The water solubility of L-BPA and
[19F]-L-FBPA were measured from supernatant of satu-
rated solution by UV absorption method. SCC-VII, a
squamous cell carcinoma cell line derived from C3H/He
mice (Department of Radiology, Kyoto University), was
maintained in Eagle’s minimum essential medium sup-
plemented with 12.5 % foetal bovine serum and penicil-
lin/streptomycin (100 U/mL). The cells were cultured at
37 °C with 5 % CO2.
Four-week-old female C3H/He mice were purchased
from CLEA Japan (Tokyo, Japan). SCC-VII cells (3.0 × 105)
were subcutaneously inoculated into the left hind legs of
C3H/He mice. Experiments were carried out 2 weeks after
the inoculation, when each tumour had reached approxi-
mately 1 cm in diameter. All of the animal experiments
were approved by the Animal Research Committee of
Kyoto University Research Reactor Institute and were
performed in accordance with the institutional laboratory
animal handling guidelines and the guidelines governing
animal care in Japan. The mice were handled according to
the recommendations for the Handling of Laboratory Ani-
mals for Biomedical Research, compiled by the Committee
on Ethical Handling Regulations for Laboratory Animal
Experiments, Kyoto University.
Preparation of L-BPA-fructose and [19F]-L-FBPA-fructose
solution
L-BPA or [19F]-L-FBPA and fructose were dissolved in dis-
tilled water at a molar ratio of 1:1.5, and then a 1.15 M ra-
tio of 1 N NaOH was added. Here, L-BPA or [19F]-L-FBPA
was mixed with fructose to increase the solubility [14]. The
mixture was stirred until L-BPA or [19F]-L-FBPA had com-
pletely dissolved, and the pH value was titrated to 7.6 with
1 N HCl. The solution was filtered through a 0.22-μm syr-
inge filter for sterilization (Merck Millipore, Massachusetts,
USA). The final concentration was set to 30 mg/ml.
Experiment 1: comparison of the pharmacokinetics of
L-BPA and [19F]-L-FBPA subcutaneously injected
L-BPA-fructose or [19F]-L-FBPA-fructose solution (500 mg/
kg body weight) was subcutaneously injected into mice into
the nuchal sites after a 3-h fast [17]. At each time point
(30 min, 1, 2, 3, and 4 h), the boron concentrations in the
blood, normal tissue, and tumour tissue were evaluated.
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Five mice were used for each time point. Totally 25 mice
were used in this experiment. The 20 % trimmed mean,
which was defined as the mean after discarding samples at
the high and low end, was used to evaluate the difference
between L-BPA and [19F]-L-FBPA in order to improve
non-normality and skew in population distribution in this
study. Time courses of the boron compounds in blood and
tissues were defined as bioequivalent if the 90 % confidence
intervals for the ratios of the average values of parameters
fall within the acceptance limits of 0.80–1.25 for the
maximum concentration and areas under the blood boron
concentration curve (AUC) [18].
Experiment 2: comparison of the pharmacokinetics of
L-BPA and [19F]-L-FBPA continuously administered
L-BPA-fructose or [19F]-L-FBPA-fructose solution (500 mg/
kg body weight) was continuously and subcutaneously
injected at a constant rate of drip infusion into the nuchal
sites after a 3-h fast using a syringe pump (KDS100;
Muromachi Kikai Co., Ltd., Tokyo, Japan) without anaes-
thesia. Totally seven mice (four mice of L-BPA group and
three mice of [19F]-L-FBPA group) were used in this experi-
ment. First, each fructose solution of boron compound was
continuously infused at a rate of 200 mg/kg body weight/h
for 2 h. Next, the infusion rate was reduced to 100 mg/kg
body weight/h for 1 h as in the clinical protocol for human
patients previously reported [19]. After 3 h from the onset
of drip infusion, tissue samples were excised immediately,
and the boron concentrations in the blood, normal tissue,
and tumour tissue were measured.
Measurements of the boron concentration
Blood and tissue samples were digested with perchloric
acid (60 %) and hydrogen peroxide (30 %) for 24 h at
75 °C. The boron concentration in each sample was
determined by ICP-AES (iCAP 6000; Thermo Fisher
Scientific Inc., Massachusetts, USA) and was normalized
as μg/g. The N/B, T/B, and T/N ratios were calculated,
and the 20 % trimmed mean values of each ratio were
used for statistical analysis.
Statistical analysis
The data are expressed as the mean ± standard deviation.
The differences between the L-BPA group and [19F]-L-
FBPA group and the subcutaneous injection group and
continuous injection group were analysed by Welch’s t-
test. The differences of N/B, T/B, and T/N ratio between
the values 3 h after a single injection in Experiment 1
and the values after continuous drip infusion in Experi-
ment 2 were analysed by a non-parametric ANOVA. P
values less than 0.05 were considered to be statistically
significant. All of the statistical analyses were per-
formed using JMP Pro 11 software (SAS Institute Inc.,
Cary, NC, USA).
Results
Properties of L-BPA and [19F]-L-FBPA
The properties of L-BPA and [19F]-L-FBPA are shown in
Table 1. The melting point and solubility in water of L-
BPA were different from those of [19F]-L-FBPA. The acid
dissociation constant of the amino group (pKb1) was
also different between L-BPA and [19F]-L-FBPA.
Experiment 1: comparison of the pharmacokinetics of
L-BPA and [19F]-L-FBPA subcutaneously injected
The results of the pharmacokinetics of L-BPA and [19F]-
L-FBPA by subcutaneous injection are shown in Fig. 2.
The maximum values of the blood boron concentration
of L-BPA and [19F]-L-FBPA were 24.6 and 23.7 μg/g, re-
spectively. The AUC calculated using the linear trapez-
oidal rule of L-BPA and [19F]-L-FBPA were 57.4 μg ∙ hour/
g (standard error 2.11) and 49.5 μg ∙ hour/g (standard
error 2.32), respectively. Figures 3 and 4 show the transi-
tion of the N/B, T/B, and T/N ratios of each normal tissue
and tumour tissue. There were no differences in the tran-
sition of the N/B, T/B and T/N ratios between the L-BPA
group and [19F]-L-FBPA group. The 90 % confidence in-
tervals of the maximum concentrations of boron in blood,
intestine, liver, lung, tongue, skin, muscle, brain, and
tumour were 1.19, 1.47, 1.15, 1.42, 1.30, 1.31, 1.58, 1.10,
and 1.24, respectively. The 90 % confidence intervals of
AUC in blood, intestine, liver, lung, tongue, skin, muscle,
brain, and tumour were 1.33, 1.08, 1.05, 1.08, 1.22, 1.29,
1.13, 1.08, and 1.07, respectively. The 90 % confidence in-
tervals of the maximum concentration of boron in blood
were within ranges of 0.80–1.25, while that of AUC in
blood were out of the ranges. That of the maximum con-
centrations and AUC in liver and tumour were within the
ranges. However, that of the maximum concentrations in
intestine, tongue, and muscle were out of the ranges, while
that of AUC in these organs were within the ranges.
Experiment 2: comparison of the pharmacokinetics of
L-BPA and [19F]-L-FBPA continuously administered
The boron concentrations of the blood, normal tissue,
and tumour tissue after the continuous infusion of L-
BPA and [19F]-L-FBPA are shown in Table 2. There were
no significant differences in the boron concentrations
between the L-BPA group and [19F]-L-FBPA group.
Table 3, Fig. 3 (black circles at the time point of 3 h)
Table 1 Physicochemical property of L-BPA and [19F]-L-FBPA
L-BPA [19F]-L-FBPA
Melting point 285–298 °C 266–269 °C
Solubility (water, 25 °C) 1.6 g/L 2.6 g/L
Acid dissociation constant pKa: 2.10 (−COOH) pKa: 2.11 (−COOH)
pKb1: 8.43 (−NH2) pKb1: 7.71 (−NH2)
pKb2: 9.79 (−B(OH)2) pKb2: 9.49 (−B(OH)2)
Watanabe et al. BMC Cancer  (2016) 16:859 Page 4 of 10
show the N/B ratio and T/B ratio of the L-BPA group
and [19F]-L-FBPA group under the continuous-infusion
protocol. No significant difference was observed in the
N/B and T/B ratios of the intestine, liver, kidney, tongue,
skin, and brain between the L-BPA group and [19F]-
L-FBPA group. The trend between the L-BPA group
and [19F]-L-FBPA group was also the same regarding
the T/N ratio under the continuous-infusion protocol
(Table 4 and Fig. 4).
Experiment 1 and 2: comparison between the single-
injection protocol and continuous-infusion protocol
Comparing the single-injection protocol and continuous-
infusion protocol, the N/B and T/N ratios of the
continuous-infusion group were different from those
of the single-injection group (Fig. 3). The N/B ratio of the
continuous-infusion protocol was lower than that of the
single-injection protocol, while the T/N ratio of the
continuous-infusion protocol was higher than that of the
single-injection protocol. In contrast, the T/B ratio of the
continuous-infusion protocol corresponded with that of
the single-injection protocol at 1, 2, and 3 h after L-BPA
or [19F]-L-FBPA injection (Fig. 3). N/B, T/B, and T/N ratio
of liver and tumour tissue had no statistical difference
between administration protocols both in L-BPA group
and L-FBPA group. On the other hand, N/B and T/N ratio
of tongue, muscle, and brain had significant difference
between administration protocols both in L-BPA group
and L-FBPA group (Figs. 3 and 4).
Discussion
This study is the first examination comparing the
pharmacokinetics of L-BPA and [19F]-L-FBPA under the
condition of the same dose and protocol (ICP-AES) as
that of a mouse model using the cold isotope of [18F]-L-
FBPA. Previous studies have compared the radioactivity
accumulation of [18F]-L-FBPA in tumour and normal
tissues by PET as well as the boron concentrations of L-
Fig. 2 Transition of the boron concentrations in blood, normal tissue, and tumour tissue. This figure shows the transition of the boron concentrations
in blood, normal tissue, and tumour tissue. a Boron concentrations after L-BPA subcutaneous injection. b Boron concentrations after [19F]-L-FBPA
subcutaneous injection
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BPA in tumour and normal tissues by ICP-AES [16, 20, 21].
Ishiwata and colleagues examined the effect of L-BPA
loading on the uptake of [18F]-L-FBPA by measuring
the radioactivity of 18F in B16 melanoma-bearing mice
[20]. These authors found that the uptake of [18F]-L-
FBPA was competitively inhibited by L-BPA loading
both in the tumour tissue and muscle. Thus, the uptake
mechanism of [18F]-L-FBPA is thought to be similar to
that of L-BPA. However, the similarities in the the time
courses of the N/B and T/N ratios between L-BPA and
[18F]-L-FBPA remain controversial. Wang et al. exam-
ined the difference in the time course after injection of
the L-BPA fructose complex and the [18F]-L-FBPA fruc-
tose complex in a glioma-bearing rat model [21]. These
authors found that the T/N ratios of [18F]-L-FBPA were
higher than those of L-BPA at any time point, although
the uptake characteristics of the L-BPA fructose com-
plex and [18F]-L-FBPA fructose complex in the tumour
tissue were similar, with a maximum observed at 1 h
after administration. Hanaoka and colleagues demon-
strated a significant correlation between the amount of
boron accumulation estimated by PET after injection of
the tracer dose of [18F]-L-FBPA and that measured by
ICP-AES after the injection of 40 mg of the L-BPA
fructose complex (r = 0.92, p < 0.05). However, the ex-
perimental conditions of these studies were different
regarding the dosage of L-BPA and [18F]-L-FBPA
(therapeutic dose vs. tracer dose), the method used to
measure the boron concentration (ICP-AES vs. PET),
and the use of the fructose complex. Additionally, no
previous study has compared the single-injection
method of L-BPA or [18F]-L-FBPA and the continuous-
infusion method of these boron compounds, which is
the clinical protocol for L-BPA administration used
widely in cancer patients. The results of this study
showed no apparent difference between L-BPA and
[19F]-L-FBPA in pharmacokinetics or boron accumula-
tion in tissues. However, certain tendencies were
Fig. 3 Transition of the tissues to blood ratio of boron concentrations. This figure shows the time transition of each normal tissue to blood ratio
and tumour tissue to blood ratio of boron concentrations. The brain to blood ratio increased over time because the boron compounds in the
brain were retained 4 h after the injection of L-BPA or [19F]-L-FBPA, while the boron in the blood was excreted over time. There was no difference
in the transition of the normal tissue to blood ratio and tumour tissue to blood ratio between the L-BPA group and [19F]-L-FBPA group. In this figure,
the difference between the administration protocols is indicated. The mean boron concentration of the L-BPA group and [19F]-L-FBPA group
by continuous infusion is denoted as black circles at the time point of 3 h after the start of infusion in this figure. Each continuous infusion
value was substituted by the mean value of L-BPA and L-FBPA in continuous infusion protocol. Star signs (*) means significant difference between
administration protocols (p < 0.05)
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observed between the single-injection protocol and
continuous-infusion protocol regarding the N/B, T/B,
and T/N ratios between L-BPA and [19F]-L-FBPA.
Two aspects in the present study are particularly dif-
ferent from the data of previous studies. First, organs
that include air such as the intestine and lung could be
evaluated without underestimation by the same protocol
in both the L-BPA group and [19F]-L-FBPA group in this
study. In particular, [18F]-L-FBPA accumulation in hol-
low organs or the lung is significantly underestimated by
PET based on the maximum or average counts [16]. In
this study, the boron concentrations of the intestine and
lung showed no significant difference between the L-
BPA group and [19F]-L-FBPA group. Second, we com-
pared the pharmacokinetics of two administration
protocols: single injection and continuous infusion. L-BPA
and [19F]-L-FBPA showed the same boron accumulation
characteristics in normal and tumour tissues. However,
the N/B, T/B and T/N ratios of the continuous-infusion
protocol showed different tendencies from those of the
single-injection protocol in some organs.
Comparing the single-injection protocol with the
continuous-infusion protocol, the T/N ratio by the
continuous-infusion protocol was higher than that by
the single-injection protocol in many normal tissues
such as the brain, tongue, lung, intestine, skin, and
muscle (Fig. 3). The N/B ratio in those normal tissues
with the continuous-infusion protocol was lower than
that by the single-injection protocol measured 1 h after
injection. However, the N/B and T/N ratios of the liver
Fig. 4 Transition of the tumour tissue to normal tissue ratio of boron concentrations. This figure shows the time transition of each tumour tissue
to normal tissue ratio of boron concentrations. There were no differences in the transition of the tumour tissue to normal tissue ratio between
the L-BPA group and [19F]-L-FBPA group. Each continuous infusion value was substituted by the mean value of L-BPA and L-FBPA in continuous
infusion protocol. Star signs (*) means significant difference between administration protocols (p < 0.05)
Table 2 The boron concentrations of the blood and tissues under the continuous-infusion protocol
Blood Brain Liver Tongue Skin Lung Muscle Intestine Tumour
L-BPA (μg/g) 13.42 ± 1.26 4.97 ± 0.54 12.11 ± 1.82 13.62 ± 5.15 15.65 ± 2.77 15.82 ± 1.51 12.41 ± 1.19 16.45 ± 2.91 21.11 ± 3.15
L-FBPA (μg/g) 13.19 ± 1.18 4.61 ± 2.28 15.63 ± 3.15 12.14 ± 1.08 13.75 ± 3.08 14.78 ± 1.64 9.69 ± 1.3 15.33 ± 0.88 20.17 ± 6.49
p value 0.81 0.81 0.18 0.61 0.45 0.43 0.052 0.51 0.83
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and the T/B ratio were almost the same between the
continuous-infusion protocol and single-injection proto-
col (Fig. 3). In this study, we used continuous subcutane-
ous injection protocol instead of continuous intravenous
injection protocol. This is because we concerned the
possible effects of anesthesia during continuous intra-
venous injection to circulation dynamics, blood flow,
and tissue distribution of boron compounds. The bio-
logical effectiveness of neutron capture therapy depends
on the administration dose of L-BPA [17, 22] and the N/
B ratio [22, 23]. In this study, we found a difference in
the N/B and T/B ratios between the single-injection
protocol and continuous-infusion protocol. In applying
the N/B or T/N ratios measured by the [18F]-L-FBPA
PET study to dosimetry in the clinical setting, we
should consider the possibility of the difference be-
tween administration protocols. Further studies, includ-
ing pharmacokinetic studies with various animal
species, treatment studies using neutron irradiation
with different administration protocols, and examina-
tions regarding the difference in the biological effective-
ness using the infusion protocol, are needed to
presisely estimate the pharmacokinetics in humans and
to define both offset values between the values mea-
sured by PET and tumour dosimetry in clinical situa-
tions and appropriate time points of PET values after
the single injection of [18F]-L-FBPA.
There are some limitations to this study. First, our
measurement methods by ICP-AES could not evaluate
the microdistribution of boron atoms in tissue compo-
nents. GM Morris and colleagues showed the different
microdistribution patterns of boron atoms in murine
tongue mucosa following the administration of L-BPA or
BSH [24]. BNCT is based on the neutron capture reac-
tion resulting in two particles (4He and 7Li) whose range
is limited to the diameter of a single cell (5–9 μm).
Therefore, microdistribution impacts both tumour tar-
geting and normal tissue damage. In this study, we did
not evaluate microdistribution because we focused on
the equivalence of [19F]-L-FBPA over L-BPA and because
[18F]-L-FBPA PET values in clinical settings represent the
“macro” distribution similar to the boron concentrations
measured by ICP-AES. However, microdistribution should
be examined in evaluating treatment results or the equiva-
lence of biological effects rather than the pharmacokinet-
ics of boron compounds [25].
The second limitation is the identicalness of [18F]-L-
FBPA and [19F]-L-FBPA. The change of chemical struc-
ture of [18F]-L-FBPA may happen by nuclear reaction of
18F. This would cause the difference of the pharmaco-
kinetics between [18F]-L-FBPA and [19F]-L-FBPA. Previ-
ous report that studied the metabolism of [18F]-L-FBPA
in vivo mouse model showed that [18F]-L-FBPA was
stable to metabolic alteration in plasma and tumour tis-
sue [13]. Thus, we assumed the pharmacokinetics of
[18F]-L-FBPA and [19F]-L-FBPA were identical in this
study. The third limitation of our study was the possibil-
ity of [18F]-L-FBPA metabolization. The cleavage of
fluorine from [18F]-L-FBPA leads to the underestimation
of [18F]-L-FBPA accumulation in normal and tumour
tissues as measured by PET [20]. In this study, we evalu-
ated the accumulation of [19F]-L-FBPA using the same
methods as those for the evaluation of L-BPA accumula-
tion. Thus, the metabolization of [19F]-L-FBPA did not
affect the results of our study. However, we must con-
sider the stability of [18F]-L-FBPA and impact of [18F]-L-
FBPA metabolites in boron accumulation in normal and
tumour tissues when the long-term dynamic study of
[18F]-L-FBPA is scheduled. For instance, a previous
study showed the stability of the tracer dose of [18F]-L-
FBPA for metabolic alterations over 6 h [26]. In addition,
if 18F is separated from [18F]-L-FBPA in other organs
such as liver and intestine by some enzymatic metabol-
ism, free 18F would be released to blood flow and the de-
position of 18F to bone should be observed in dynamic
PET imaging study in clinical situations as observed in
[18F]-NaF PET imaging. However, no such image is ob-
tained in dynamic PET study of [18F]-L-FBPA in clinical
situations. Thus, we believe that an [18F]-L-FBPA PET
dynamic study with a maximum duration of 6 h can be
Table 3 The tissue to blood ratios of boron concentrations under the continuous-infusion protocol
Intestine Liver Kidney Lung Tongue Skin Muscle Brain Tumour
L-BPA (μg/g) 1.22 ± 0.13 0.90 ± 0.09 3.80 ± 1.21 1.18 ± 0.01 1.17 ± 0.167 1.02 ± 0.38 0.93 ± 0.06 0.37 ± 0.05 1.58 ± 0.20
L-FBPA (μg/g) 1.17 ± 0.04 1.18 ± 0.19 4.40 ± 1.04 1.12 ± 0.03 1.03 ± 0.152 0.92 ± 0.01 0.74 ± 0.09 0.35 ± 0.15 1.52 ± 0.42
p value 0.46 0.11 0.52 0.048 0.33 0.65 0.044 0.80 0.85
Table 4 The tumour tissue to the normal tissue ratios under the continuous-infusion protocol
Intestine Liver Kidney Lung Tongue Skin Muscle Brain
L-BPA (μg/g) 1.31 ± 0.26 1.77 ± 0.34 0.46 ± 0.19 1.34 ± 0.16 1.36 ± 0.07 1.64 ± 0.34 1.70 ± 0.14 4.24 ± 0.31
L-FBPA (μg/g) 1.31 ± 0.39 1.34 ± 0.56 0.37 ± 0.15 1.36 ± 0.36 1.47 ± 0.30 1.65 ± 0.44 2.05 ± 0.35 4.60 ± 0.72
p value 0.99 0.32 0.51 0.92 0.98 0.58 0.22 0.48
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applicable for the evaluation of L-BPA accumulation in
clinical settings.
Conclusions
We showed the equivalence of the pharmacokinetics of L-
BPA and [19F]-L-FBPA under the condition of the same
fructose complex and dose using the same protocol as that
for a subcutaneous tumour mouse model. Next, we evalu-
ated the effects of the administration protocol on the
boron distribution in normal and tumour tissues. Some
differences were observed between the single-injection
protocol and continuous-infusion protocol. In applying
the measured values in the F-BPA PET study for dosim-
etry in BNCT, the possible difference in the N/B and T/N
ratios between [18F]-L-FBPA single injection and L-BPA
continuous infusion should be carefully considered. This
study provides useful information for the future clinical
application of [18F]-L-FBPA PET in clinical dose calcula-
tion for BNCT in cancer therapy.
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